TY  - JOUR
AU  - Hanna, Glenn J
AU  - Guenette, Jeffrey P
AU  - Chau, Nicole G
AU  - Sayehli, Cyrus M
AU  - Wilhelm, Christian
AU  - Metcalf, Robert
AU  - Wong, Deborah J
AU  - Brose, Marcia
AU  - Razaq, Mohammad
AU  - Pérez-Ruiz, Elisabeth
AU  - Cohen, Ezra E W
AU  - Aggarwal, Rahul
AU  - Scholz, Catherine
AU  - Gualberto, Antonio
AU  - Ho, Alan L
PY  - 2020
DO  - 10.1002/cncr.33036
UR  - http://hdl.handle.net/10668/15767
T2  - Cancer
AB  - To the authors' knowledge, there are no approved therapies for recurrent, metastatic (R/M) salivary gland carcinoma (SGC), but molecularly targeted therapies warrant ongoing investigation. In the current study, the authors have reported on the...
LA  - en
KW  - HRAS
KW  - rare cancers
KW  - salivary cancer
KW  - targeted therapy
KW  - tipifarnib
KW  - Adult
KW  - Aged
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Metastasis
KW  - Neoplasm Recurrence, Local
KW  - Progression-Free Survival
KW  - Proto-Oncogene Proteins p21(ras)
KW  - Quinolones
KW  - Salivary Gland Neoplasms
KW  - Treatment Outcome
TI  - Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer.
TY  - research article
VL  - 126
ER  -